These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 10304476)
1. Drug abuse testing: issues and opportunities. Gardner J; Mehl PE Hosp Technol Ser; 1988 May; 7(12):1-11. PubMed ID: 10304476 [No Abstract] [Full Text] [Related]
2. Launching a DNA lab. Molecular pathology, Part 1. Farkas DH MLO Med Lab Obs; 1995 May; 27(5):42-8; quiz 54-5. PubMed ID: 10142672 [No Abstract] [Full Text] [Related]
3. Drug abuse screening: get your lab's share of a booming market. De Cresce RP; Lifshitz MS MLO Med Lab Obs; 1987 Oct; 19(10):31-4. PubMed ID: 10317952 [No Abstract] [Full Text] [Related]
4. Heart institutes provide collaboration opportunities. Kania AJ Health Care Strateg Manage; 1993 May; 11(5):1, 20-3. PubMed ID: 10125590 [No Abstract] [Full Text] [Related]
5. Beyond traditional quality control. How to check costs and quality of point-of-care testing. Hortin GL MLO Med Lab Obs; 1997 Sep; 29(9):31-2, 34, 36-7. PubMed ID: 10174098 [No Abstract] [Full Text] [Related]
6. How to improve the quality of waived tests. Mitchell B; Murray C Fam Pract Manag; 2006 Oct; 13(9):49-52. PubMed ID: 17076111 [No Abstract] [Full Text] [Related]
7. Stat testing, Part 2. Stat testing triumphs and disappointments. Trotto NE MLO Med Lab Obs; 1994 Dec; 26(12):26-31. PubMed ID: 10139359 [No Abstract] [Full Text] [Related]
8. Bedside testing--considerations for design and maintenance of a quality assurance plan. Ogram DM Can J Med Technol; 1988 Aug; 50(3):184-5. PubMed ID: 10302830 [No Abstract] [Full Text] [Related]
9. The impact of DRGs after year 4. Part II: Controlling expense, chasing revenue. Gore MJ MLO Med Lab Obs; 1987 Dec; 19(12):35-9. PubMed ID: 10312343 [No Abstract] [Full Text] [Related]
10. Saving laboratory records: what, how, how long? Baer D MLO Med Lab Obs; 2004 May; 36(5):10-1, 14-6; quiz 18-20. PubMed ID: 15179913 [No Abstract] [Full Text] [Related]
11. Protocols for bedside testing. Part II. Belsey R; Baer DM MLO Med Lab Obs; 1988 Mar; 20(3):63-4, 69-72. PubMed ID: 10286475 [No Abstract] [Full Text] [Related]
12. Competitive dynamics in pharmaceuticals. Murphy MN; Smith MC; Barnes JH; Szeinbach SL J Health Care Mark; 1995; 15(2):24-33. PubMed ID: 10144664 [No Abstract] [Full Text] [Related]
14. The physicians' view of the lab, Part 2. Doctors speak their minds on lab profiles and problems. Jahn M MLO Med Lab Obs; 1997 Jun; 29(6):32, 34, 36-8. PubMed ID: 10173035 [No Abstract] [Full Text] [Related]
15. New product lines planning priorities. Health Care Strateg Manage; 1991 Jan; 9(1):4-5. PubMed ID: 10108625 [No Abstract] [Full Text] [Related]
16. Using a call-processing system to increase productivity. Armstrong LA; Gladish MD MLO Med Lab Obs; 1993 Nov; 25(11):34-6, 38. PubMed ID: 10130115 [No Abstract] [Full Text] [Related]
17. Monitoring the quality of testing performed by referral laboratories. Wilding P; Hall R MLO Med Lab Obs; 1994 Mar; 26(3):36-40. PubMed ID: 10138086 [No Abstract] [Full Text] [Related]
18. Satellite laboratories. A cost-benefit study. Kiechle FL; Aulakh V MLO Med Lab Obs; 1998 Nov; 30(11):44-5, 48, 50. PubMed ID: 10339255 [No Abstract] [Full Text] [Related]
19. Mandatory drug testing in the United States. Opportunities and challenges for the medical review officer. Gerson B; Hahn R Clin Lab Med; 1990 Sep; 10(3):517-29. PubMed ID: 2253448 [TBL] [Abstract][Full Text] [Related]